Pharsight

Definity is owned by Lantheus Medcl.

Definity contains Perflutren.

Definity has a total of 8 drug patents out of which 0 drug patents have expired.

Definity was authorised for market use on 31 July, 2001.

Definity is available in injectable;intravenous dosage forms.

Definity can be used as method of using the drug substance/drug product for ultrasound imaging.

The generics of Definity are possible to be released after 04 May, 2037.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10022460	LANTHEUS MEDCL	Lipid-encapsulated gas microsphere compositions and related methods	Dec, 2035 (12 years from now)
US11395856	LANTHEUS MEDCL	Lipid-encapsulated gas microsphere compositions and related methods	Dec, 2035 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583207	LANTHEUS MEDCL	Lipid-encapsulated gas microsphere compositions and related methods	Dec, 2035 (12 years from now)
US10583208	LANTHEUS MEDCL	Methods for making ultrasound contrast agents	Mar, 2037 (14 years from now)
US11529431	LANTHEUS MEDCL	Methods for making ultrasound contrast agents	Mar, 2037 (14 years from now)
US11266750	LANTHEUS MEDCL	Methods for making ultrasound contrast agents	Mar, 2037 (14 years from now)
US9789210	LANTHEUS MEDCL	Methods for making ultrasound contrast agents	Mar, 2037 (14 years from now)
US10588988	LANTHEUS MEDCL	Methods and devices for preparation of ultrasound contrast agents	May, 2037 (14 years from now)